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Abstract 
There is currently no approved neuroprotective pharmacotherapy for acute conditions such 
as stroke and cerebral asphyxia. One of the reasons for this may be the multiplicity of cell 
death mechanisms, because inhibition of a particular mechanism leaves the brain vulnerable 
to alternative ones. It is therefore essential to understand the different cell death mechanisms 
and their interactions. We here review the multiple signaling pathways underlying each of the 
three main morphological types of cell death – apoptosis, autophagic cell death, and necrosis 
– emphasizing their importance in the neuronal death that occurs during cerebral ischemia 
and hypoxia-ischemia, and we analyze the interactions between the different mechanisms. 
Finally, we discuss the implications of the multiplicity of cell death mechanisms for the design 
of neuroprotective strategies. 
 
 3 
 
Contents  
1. Introduction ................................................................................................................. 5 
1.1. Excitotoxicity………………………………………………………………………………….6 
2. Type 1 cell death: apoptosis ...................................................................................... 6 
2.1. Morphological definition of apoptosis ...................................................................... 6 
2.2. Brief summary of the intrinsic apoptotic pathway ............................................... 7 
2.2.1. Caspase-dependent intrinsic pathway ................................................................... 9 
2.2.2. Caspase-independent intrinsic pathway .............................................................. 10 
2.3. Brief summary of the extrinsic apoptotic pathway ................................................ 11 
2.4. Apoptosis in excitotoxicity and cerebral hypoxia/ischemia .............................. 12 
3. Type 2 cell death – autophagic ................................................................................ 16 
3.1. Different types of autophagy ................................................................................ 17 
3.2. Summary of the molecular mechanisms of autophagy ..................................... 18 
3.2.1. Phase of induction ................................................................................................. 18 
3.2.2. Phase of autophagosome formation ...................................................................... 20 
3.2.3. Phase of autophagosome maturation .................................................................... 23 
3.3. Difficulties concerning the demonstration of enhanced autophagy ................. 24 
3.4. The term “autophagic cell death” ............................................................................ 25 
3.5.  Autophagy in the mediation of cell death............................................................ 26 
3.6. Autophagy in excitotoxicity and cerebral ischemia ........................................... 29 
4. Cell death of type 3 - necrotic .................................................................................. 31 
4.1. Morphological definition of type 3 cell death ...................................................... 31 
4.2. Neuronal necrosis in excitotoxicity and cerebral ischemia ............................... 33 
5. Parameters influencing the cell death mechanisms involved in cerebral hypoxic-
ischemic damage ................................................................................................................. 36 
5.1. Brain maturity ........................................................................................................ 36 
5.2. Gender differences ................................................................................................ 38 
6. Interconnections between the different types of cell death .................................. 39 
6.1. Interconnections between necrosis and apoptosis ........................................... 39 
6.2. Interconnections between autophagy and apoptosis ........................................ 41 
6.3. Interconnections between autophagy and necrosis .......................................... 46 
7.  Development of neuroprotective strategies in the light of the multiple cell death 
mechanisms ......................................................................................................................... 46 
8.  Conclusions............................................................................................................... 50 
Acknowledgements .......................................................................................................... 50 
References ........................................................................................................................ 51 
 
 
 
 
 
 
 4 
 
1. Introduction 
 
Despite a considerable research effort, there is still no approved neuroprotective 
pharmacotherapy for acute neurological conditions such as stroke (Stankowski and Gupta, 
2011; Yuan, 2009) and neonatal cerebral asphyxia (van Bel and Groenendaal, 2008). The 
reasons for this are multiple, but one of the problems appears to be the multiplicity of cell 
death mechanisms, because inhibition of a particular death mechanism will be ineffective if 
alternative mechanisms are able to kill the cell. It is therefore essential to understand the 
different cell death mechanisms and their interactions. 
Morphological studies indicate that there are three main types of cell death (Fig. 1): 
type 1 or apoptosis, type 2 or autophagic death, and type 3 or necrotic/cytoplasmic death. 
Initial arguments for this trichotomy focused on cell death during normal development 
(Clarke, 1990), but a similar classification appears to be valid in both adult and neonatal 
pathological situations including ischemic brain damage (Bredesen, 2008; Clarke, 1999). The 
coverage of neonatal ischemic (including hypoxic-ischemic) models in the present review is 
limited to ages at which the brain damage is mainly in the gray matter - after postnatal day 
(P) 7. Very early cerebral ischemia (P2-P4) causes primarily white matter lesions, by entirely 
different mechanisms, which is beyond our present concern. 
We here review critically, in the context of cerebral ischemia and hypoxia-ischemia, 
the available evidence on the multiple mechanisms underlying the three types of cell death. 
In particular, we focus on four problem areas. 1. The factors that determine whether a given 
type predominates. 2. The interactions between the multiple mechanisms and the hybrid 
forms of cell death that can result. 3. The current controversy about whether autophagy is a 
death mediator in type 2 cell death (Clarke and Puyal, 2012; Shen et al., 2012; Yuan and 
Kroemer, 2010). 4. The challenge that the multiple mechanisms constitute for the design of 
neuroprotective strategies. 
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 1.1. Excitotoxicity 
The multiplicity of cell death mechanisms in excitotoxicity and cerebral ischemia 
results from the fact that these events trigger multiple pathways. Excitotoxicity, defined as 
toxicity due to the excessive activation of ionotropic and metabotropic glutamate receptors, is 
well known to be the main cell death mechanism in cerebral ischemia and hypoxia-ischemia. 
Glutamate receptor activation depolarizes the neuron and raises the level of intracellular 
calcium due to its influx through N-methyl-D-aspartate (NMDA) channels and other voltage-
sensitive channels and its release from intracellular stores, which triggers a variety of death 
pathways and leads organelle dysfunction, the production of free radicals and nitric oxide, 
and the activation of proteases, lipases and kinases). Excitotoxicity is not the only 
mechanism – transient receptor potential channels, acid-sensing channels, pannexins and 
hemichannels can all play a role as well (Tymianski, 2011) – but we here focus on 
excitotoxicity since it is the main toxic mechanism in hypoxic and hypoxic-ischemic brain 
injury. Moreover, the best understood influences of the nonexcitotoxic mechanisms converge 
on the same intracellular pathways as excitotoxicity; for example, transient receptor potential 
channels and acid-sensing channels mediate the entry of calcium and sodium (Tymianski, 
2011).  
 
2. Type 1 cell death: apoptosis 
 
2.1 Morphological definition of apoptosis 
  
Type 1 cell death, or apoptosis, has also been called the nuclear type of cell death 
because it is characterized by striking morphological changes in the nucleus: compaction of 
chromatin and nuclear condensation leading to its pyknosis and then its fragmentation (Fig. 
1). These modifications of the nuclear morphology are accompanied by shrinkage of the 
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cytoplasm and a distorsion of the plasma membrane into folds that break off to form apoptotic 
bodies. These portions of the cell will be degraded by heterophagy after phagocytosis, by the 
lysosomes of a phagocyte. There can also be a loss of ribosomes from the rough 
endoplasmic reticulum (ER) and from the polysomes, but most of the other organelles appear 
morphologically normal, at least initially (Clarke, 1990) (Fig. 1).  
Historically, apoptosis is the best known and best characterized form of programmed 
cell death, occurring naturally in most tissues during embryonic and postnatal development. 
In the first phase of neuronal death, during neurogenesis, the typology of cell death has not 
been studied in depth, but the main type seems to be apoptotic (Valenciano et al., 2009). The 
second phase of neuronal death, which occurs while the neuronal connections are being 
formed, involves all three types of cell death. Like the other two types, apoptosis has been 
well demonstrated ultrastructurally in numerous situations (Clarke, 1990). 
Apoptosis is the type of cell death whose molecular mechanisms have been the most 
intensely studied. It can be activated by two main pathways: an intrinsic pathway that 
depends on the integrity of the mitochondria, and an extrinsic one that is activated by 
extracellular signals resulting from the binding of extracellular proteins to so called “death 
receptors” on the cell membrane (Fig. 2).  
 
2.2. Brief summary of the intrinsic apoptotic pathway 
 
The intrinsic pathway of apoptosis depends on a set of proteins belonging to the Bcl-2 
family (which takes its name from “B-cell lymphoma 2”, founding member of the Bcl-2 family 
of apoptosis regulators). These proteins are sensitive to intracellular stress originating from 
the ER, the cytoskeleton, the nucleus and the mitochondria. The classification of these 
proteins is based mainly on the type and number of Bcl-2 homology domains (BH) that they 
possess. The induction of apoptosis depends on the balance between the two main classes 
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of Bcl-2 family proteins, which are as follows (Antonsson and Martinou, 2000; Bredesen, 
2007; Llambi et al., 2011) (Fig. 2): 1) The anti-apoptotic members such as Bcl-2, Bcl-xL (B-
cell lymphoma-extra large) and Mcl-1 (Myeloid cell leukemia-1) possess 3 to 4 BH domains 
(BH1-4) and prevent apoptosis by sequestering the pro-apoptotic members. 2) The pro-
apoptotic members are divided into two sub-groups: a) members such as Bax (Bcl-2–
associated X protein) and Bak (Bcl-2 homologous antagonist killer), with multiple BH domains 
(BH1-3), contribute directly to the permeabilization of the mitochondrion whereas b) some 
“BH3-only” members, such as PUMA (p53 upregulated modulator of apoptosis) and Bad (Bcl-
2-associated death promoter), are sensitizers, inhibiting anti-apoptotic proteins by 
sequestering them and thus allowing the liberation of the pro-apoptotic BH1-3 members. 
Other members of the “BH3-only” category, such as Bim (Bcl-2-interacting mediator of cell 
death) and tBid (truncated BH3 interacting-domain death agonist), are termed activators, 
playing more active roles in the permeabilization of the mitochondrion. 
The mitochondrion is a reservoir of apoptotic factors: cytochrome c (12kDa), 
Smac/Diablo (second mitochondria-derived activator of caspases/direct IAP binding protein 
with low pI) (27kDa), AIF (Apoptosis inducing factor) (67kDa), endonucleaseG (~34kDa), 
Omi/HtrA2 (High temperature requirement protein A2) (48kDa). These are all located in the 
intermembrane space. Even in healthy mitochondria, the outer mitochondrial membrane 
(OMM) is permeable to very small molecules (less than 5kDa), but under the influence of 
apoptotic signals, the proteins Bax and Bak make the OMM permeable to larger proteins 
causing various apoptotic factors to be released into the cytosol. Thus Bax and Bak are 
major effectors of apoptosis as their absence protects cells from many apoptotic stimuli (Wei 
et al., 2001). The three BH3-only proteins tBid, Bim and PUMA are essential activators of 
Bax and Bak (Ren et al., 2010). While Bak is constitutively present in the OMM, Bax is mainly 
cytosolic in healthy cells, and Bax recruitment to the OMM is dependent on tBid (Martinou 
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and Youle, 2011). How the OMM permeabilization is achieved remains unclear (reviewed in 
(Garcia-Saez, 2012; Martinou and Youle, 2011; Tait and Green, 2010). The most commonly 
established model is the formation of a large pore in the OMM upon the activation and 
oligomerization of Bax and Bak (Galluzzi et al., 2007; Korsmeyer et al., 2000). Another 
emerging hypothesis is the formation of a “toroidal or lipidic pore” following interaction of 
activated Bax or Bak with OMM lipids (Hardwick and Polster, 2002). Alternatively, but less 
likely, Bax and Bak may act on the opening of other channels such as the mitochondrial 
permeability transition pore (mPTP) located at the junctions between the inner and outer 
membranes inducing the entry of water and hence mitochondrial swelling and ultimately 
rupture of the outer membrane. Whatever the way of mitochondrion permeabilization, the 
different factors released from the mitochondrion into the cytosol can activate a caspase-
dependent apoptotic pathway and a different, caspase-independent pathway (Fig. 2).  
 
 2.2.1. Caspase-dependent intrinsic pathway 
Cytochrome c, which is an essential element in the respiratory chain, is released into 
the cytosol and can play a pro-apoptotic role by interacting with Apaf-1 (adapter protein 
apoptotic protease-activating factor-1). This interaction induces a conformational change of 
Apaf-1 enabling it to form heptameters and to expose its CARD domains (caspase 
recruitment domains) whose role is to recruit the caspase-9 initiator in its inactive form 
(zymogen) into a complex (apoptosome) that promotes a process of auto-catalytic activation. 
An exchange of dADP with exogenous dATP on Apaf-1 is necessary to form an active 
apoptosome (Kim et al., 2005), however the origin of the dADP is still a subject of debate 
(Reubold and Eschenburg, 2012). The active form of caspase-9 then cleaves the effector 
caspases 3, 6 and 7 which leads in turn to their activation (Boatright et al., 2003; Bredesen, 
2007). 
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Caspases-3, -7 and -9 are inhibited by the IAP (Inhibitor of Apoptosis Protein) family of 
proteins whose members include XIAP (X-linked inhibitor of apoptosis protein) and survivin. 
When the mitochondrial proteins Smac/Diablo or Omi/HtrA2 are released into the cytoplasm 
during the apoptotic process, they inhibit the IAP members and hence disinhibit the caspases 
(Bredesen, 2007; Du et al., 2000; Martins et al., 2002). Among the targets of caspases are 
the Inhibitor of Caspase-Activated Deoxyribonuclease (ICAD), the Poly(ADP-Ribose) 
Polymerase (PARP) family members, lamin A and alpha-fodrin; their caspase-mediated 
cleavage leads to cell shrinkage, membrane blebbing, inhibition of DNA repair, chromatin 
condensation and DNA fragmentation (Earnshaw et al., 1999; Fan et al., 2005). 
Activation of the transcription factor p53 can trigger apoptosis under several stress 
conditions such as DNA damage, Ca2+ overload, hypoxia and oxidative stress. The apoptotic 
mitochondrial pathway is induced by p53 activation and p53-dependent enhanced expression 
of proapoptotic proteins like Bax, Bid, PUMA and Noxa (Culmsee and Mattson, 2005) . 
However p53 has also been demonstrated to have a transcription-independent apoptotic 
effect of due to a direct action on mitochondria leading to a substantial increase in their 
permeability (Moll et al., 2005; Speidel, 2010). 
The ER can also be involved in caspase activation. In conditions of stress (oxidative 
stress, or accumulation of proteins with a conformational abnormality) caspase-12, bound to 
the cytosolic side of the ER membrane, is activated by cleavage (by m-calpain) and can then 
activate the effector caspases (Groenendyk and Michalak, 2005). 
 
2.2.2. Caspase-independent intrinsic pathway  
A caspase-independent apoptotic pathway can be activated by some of the factors 
released by the mitochondria. These include AIF (an oxidoreductase) and endonuclease G 
(endoG), which both migrate into the nucleus, where they play a role in the fragmentation of 
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DNA (Joza et al., 2001; Susin et al., 1999). AIF is a flavoprotein that, in healthy cells, plays 
an important role in oxidative phosphorylation as a NADH oxidase. It is located in the 
mitochondrial inner membrane but during apoptosis AIF is cleaved to produce a soluble 
protein released from mitochondria into the cytosol from where it is translocated to the 
nucleus causing large-scale DNA fragmentation (Susin et al., 1999; Wang and Youle, 2009). 
EndoG, is a DNA/RNA nonspecific nuclease. In healthy cells, endoG located in mitochondria 
intermembrane space has been involved in some cellular functions such as in mitochondrial 
DNA replication (Cote and Ruizcarrillo, 1993). EndoG has by itself a DNase function (Li et al., 
2001). When released from mitochondria and in the presence of interacting partners endoG 
efficiently cleaves double-stranded DNA (Kalinowska et al., 2005; Varecha et al., 2012). 
 
2.3 Brief summary of the extrinsic apoptotic pathway  
Apoptosis can also be induced by extracellular signals which activate “death” 
receptors, including the TNF (Tumor Necrosis Factor) receptor, FasL (Fas ligand) and TRAIL 
(TNF-Related Apoptosis-Inducing Ligand) receptors. Their ligand-binding leads to the 
formation of homotrimeric proteins and to the recruitment via their cytoplasmic domain (called 
the death domain – DD) of adaptor proteins such as TRADD (TNF Receptor-Associated 
Death Domain) and FADD (Fas-Associated Death Domain) (Chinnaiyan et al., 1995; 
Kaufmann et al., 2012; Kischkel et al., 1995). The resulting complex, called DISC (Death 
Inducing Signaling Complex), recruits and assembles caspase-8 zymogens via the so called 
Death Effector Domain (DED), leading to their activation either through autoproteolytic 
cleavage or through trans-cleavage by other caspases (Schmitz et al., 2000; Schulze-Osthoff 
et al., 1998). The cFLIPs (cellular FADD-like IL-1β-converting enzyme-inhibitory proteins)) 
are inhibitors of the extrinsic apoptotic pathway since they contain two DED domains which 
compete with caspase-8 for binding to FADD (Irmler et al., 1997). 
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Thus, the extrinsic pathway converges with the intrinsic one to activate effector 
caspases 3, 6 and 7. However, there is a cross talk between the pathways at an earlier level, 
because caspase 8, once activated, cleaves Bid into tBid and thus contributes to 
permeabilization of the mitochondrion and hence activation of the intrinsic pathway at an 
early level (Li et al., 1998; Luo et al., 1998). 
   
2.4. Apoptosis in excitotoxicity and cerebral hypoxia/ischemia 
Neuronal death with apoptotic features and caspase activation occurs frequently in 
excitotoxicity and cerebral hypoxia/ischemia, although pure canonical apoptosis is rare in 
these situations. 
 Studies on human brains indicated the presence of apoptosis (activation of caspases 
3- and -9, cytochrome c release, TUNEL staining) in ischemic neurons mainly in the peri-
infarct region (Duan et al., 2010; Mitsios et al., 2007; Rami et al., 2003; Sairanen et al., 
2009). In experimental models apoptosis has been reported to be an important neuronal 
death mechanism in acute neurodegenerative conditions such as head trauma or cerebral 
ischemia (Li et al., 1995; Rink et al., 1995). In focal cerebral ischemia, apoptosis is involved 
mainly in the ischemic penumbra, the border of the ischemic region where the levels of 
oxygen and energy are sufficient to allow apoptosis to occur (Benchoua et al., 2001; 
Broughton et al., 2009; Ferrer et al., 2003) (Benchoua et al., 2001; Ferrer et al., 2003; 
Broughton et al., 2009). This penumbral cell death is delayed by several or many hours with 
respect to that occurring in the ischemic core, indicating that its mechanisms are potential 
targets for neuroprotection. In several animal models, the activation of caspases 1, 3, 8, 9 
and 11, the release of cytochrome c from mitochondria (Benchoua et al., 2001; Kang et al., 
2000) and the involvement of Bcl-2 family members (Martinou et al., 1994; Plesnila et al., 
2001) have been reported in cerebral ischemia models. In mice exposed to cerebral 
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ischemia, TAT-mediated delivery of Bcl-XL has been shown to decrease caspase activation 
and brain damage (Cao et al., 2002; Kilic et al., 2002). Caspase-3 deficiency in mice reduced 
the cortical infarct volume by more than by half following middle cerebral artery occlusion 
(MCAo) (Le et al., 2002) Furthermore, pharmacological inhibition of caspases has been 
shown to protect the brain against cerebral ischemia and to reduce the behavioral 
consequences in rodents (Braun et al., 2007; Fink et al., 1998; Fink et al., 1999; Hara et al., 
1997; Rabuffetti et al., 2000). Molecular genetic inhibition of caspases by the overexpression 
of Apaf-1-interacting protein (AIP), inhibiting thereby apoptosome-induced caspase-3 
activation, likewise enhanced neuronal survival (by 38%), in hippocampal CA1 after rat 
transient global cerebral ischemia (Cao et al., 2004) and deletion of the (pro-apoptotic) Bid 
gene was strongly neuroprotective in transient MCAo (Plesnila et al., 2001). However the 
severity and the type of ischemic insult (global ischemia, permanent or transient focal 
ischemia) influence the pattern of caspase activation and the neuroprotective efficiency of 
caspase inhibition (Li et al., 2000; Manabat et al., 2003). 
  Hypoxia-ischemia in rat pups leads to strong activation of apoptotic mechanisms 
(much more strongly than in adults), which develops progressively over several hours after 
hypoxia-ischemia (HI) and contributes to the hypoxia-ischemia induced “delayed” neuronal 
death (Nakajima et al., 2000; Northington et al., 2001b; Zhu et al., 2005). The neuronal death 
resembles apoptosis morphologically, with condensation of chromatin (Fig. 3). The affected 
neurons express cleaved caspases such as caspase 3, and in rodent models caspase 
inhibition has been reported to be neuroprotective in some cases (Cheng et al., 1998; Han et 
al., 2002) but not in others (Joly et al., 2004; Puyal et al., 2009; Zhu et al., 2003). As in adult 
models, Tat- Bcl-XL has been shown to be neuroprotective, preventing both caspase-
dependent and independent pathways (Yin et al., 2006). In a moderate HI model in rat 
neonates, the intracerebroventricular injection of caspase inhibitor BAF (boc-Asp-fmk) 
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reduces the neuronal loss in the CA1 region of the hippocampus, provided the BAF is 
administered before the HI (Adachi et al., 2001; Zhu et al., 2005), and gives substantial 
protection in the cortex and striatum even when the BAF is given 3h after HI (Cheng et al., 
1998). In a more severe model, pretreatment with a specific inhibitor of caspase-3 (M826) 
likewise reduces the lesion size in the cortex, striatum and hippocampus (Han et al., 2002). 
More recently, the genetic inhibition of caspase-2 (Carlsson et al., 2011), and the inhibition of 
caspases by using a pentapeptide-based irreversible caspase inhibitor (Chauvier et al., 
2011), were shown to be strongly neuroprotective against both neonatal HI and 
excitototoxicity. In bax-/- mice there is a 36% reduction in the volume of damaged tissue in the 
hippocampus, but the activation of caspase-3 is not totally abolished in these mice because 
the extrinsic pathway of apoptosis persists and activates caspase-8 which in turn activates 
caspase-3 (Gibson et al., 2001). Similarly, a Bax-inhibiting peptide was neuroprotective 
against hypoxic-ischemic neonatal brain injury, but did not totally eliminate caspase activation 
(Wang et al., 2010). Another complication is that the elimination of caspase-3 activation 
throughout development, by its genetic deletion, exacerbates the vulnerability to hypoxia-
ischemia and increases in the size of the lesion (West et al., 2006). 
Upregulation of p53 occurs rapidly following excitotoxic insults in both adult (Li et al., 
1994; Sakhi et al., 1994) and neonatal models (Nijboer et al., 2008). Deletion of the p53 gene 
(Crumrine et al., 1994; Morrison et al., 1996) or inhibition of p53’s transcriptional effect by 
pifithrin-α both gave neuroprotection (Culmsee et al., 2001; Leker et al., 2004), and inhibition 
of the p53 pathway clearly decreased apoptotic processes (cytochrome c and Smac/Diablo 
release, caspase-3 activation, Noxa and PUMA expression, TUNEL staining) (Culmsee et al., 
2001; Leker et al., 2004; Nijboer et al., 2011). The pro-apoptotic effects of p53 are mediated 
in two ways, by its transcriptional effect (which is inhibited by pifithrin-α) and by its direct 
association with mitochondria (inhibited specifically by pifithrin-µ). The mitochondrial 
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association of p53 occurs very early, within 30min after HI (Nijboer et al., 2008), and this 
effect of p53 seems to be the more important of the two in hypoxia-ischemia, because 
pifithrin-µ was even more neuroprotective than pifithrin-α and led to a lasting improvement in 
functional outcome (Nijboer et al., 2011). 
Caspase-independent apoptosis is also involved. The translocation of AIF into the 
nucleus occurs rapidly after adult MCAo (Culmsee et al., 2005) and neonatal HI (Zhu et al., 
2003), even before the release of cytochrome c and the consequent caspase activation. Mice 
that express 60% less than normal AIF (Harlequin mice) are less sensitive than wild-type 
mice to adult MCAo (Culmsee et al., 2005) and neonatal HI, and treatment of these mice with 
the broad-spectrum caspase inhibitor Q-VD-OPh (Quinolyl-valyl-O-methylaspartyl-[2,6-
difluorophenoxy]-methyl ketone) gives a further protection against neonatal HI; the effects of 
Harlequin and caspase inhibition are additive, suggesting that their effects are on 
independent mechanisms (Zhu et al., 2007a). EndoG nuclear translocation also occurs 
rapidly in in vitro model of oxygen-glucose deprivation (Zhao et al., 2009) or following MCAo 
in mice (Nielsen et al., 2009; Wu et al., 2004) and decreased expression of endoG in 
heterozygote mice protects the hippocampi to KA-induced excitotoxic death (Lee et al., 
2005). 
The extrinsic apoptotic pathway is also triggered by cerebral ischemia. Fas, FasL and 
TRAIL expression, and caspase-8 activation, are increased in both adult cerebral ischemia 
(Benchoua et al., 2001; Buttini et al., 1996; Harrison et al., 2001; Martin-Villalba et al., 1999; 
Rosenbaum et al., 2000) and neonatal cerebral HI (Feng et al., 2003; Nijboer et al., 2009; 
Northington et al., 2001a; Szaflarski et al., 1995). Mice lacking functional Fas or FasL 
(Martin-Villalba et al., 1999; Martin-Villalba et al., 2001; Rosenbaum et al., 2000) or deficient 
for TNF (Martin-Villalba et al., 2001) are significantly protected against focal cerebral 
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ischemia. Neuronal caspase-8 deletion reduced hippocampal cell death following kainate 
(KA) injection (Krajewska et al., 2011) and caspase-8 inhibitor was neuroprotective in both 
adult MCAo (Inoue et al., 2006) and neonatal HI (Feng et al., 2003). 
In conclusion, apoptosis involvement in excitotoxicity and cerebral hypoxia-ischemia 
has been deeply investigated and characterized over the past 20 years. Nevertheless, some 
discrepancies remain concerning its role and importance in term of neuroprotection. This may 
be due to differences between the experimental models with respect to the strength of 
stimulation, the timing of therapeutic intervention, gender, strains and species used, age, 
spectrum and properties of caspase inhibitors used. Moreover, besides the fact that the 
strength of the apoptotic response needed to be evaluated in each model of acute neuronal 
disorder, another emerging problem may be the multiplicity of the apoptotic pathways 
involved (and of nonapoptotic death pathways, as is discussed below), since cells appear to 
activate alternative pathways to counteract the protective effect of apoptosis inhibition. 
Furthermore, most of the therapeutic interventions against apoptosis are focused at the level 
of caspases, which may be too low in the apoptotic cascade at a stage when the cell is 
already seriously damaged. 
 
3. Type 2 cell death – autophagic 
Autophagy is a catabolic process that is complementary to the proteasome pathway. It 
degrades long-lived proteins and organelles (including mitochondria, portions of ER, and 
peroxisomes). Even though the role of autophagy in healthy cells is moderate and 
physiological, some dying cells exhibit grossly enhanced autophagy, which has led to the 
identification of “type 2” or “autophagic” cell death as a distinct type of cell death (Figs 1, 2). 
We first provide a brief review of the cell biology of autophagy and some technical difficulties 
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in demonstrating its enhancement, before discussing the somewhat controversial question of 
its role in cell death. 
 
3.1. Different types of autophagy 
The term autophagy includes three different catabolic processes that all lead to 
degradation in lysosomes (Cuervo, 2004) (Fig. 4). Microautophagy is the sequestration of a 
part of the cytosol by an inward budding of the lysosome’s own membrane. There is only 
limited evidence for its occurrence in mammalian cells (Sahu et al., 2011). Chaperone-
mediated autophagy is specific for proteins carrying a particular sequence of 5 amino acids 
(KFERQ). This sequence is recognized by a chaperone protein (hsc73) and some co-
chaperones that direct it to the lysosome whose membrane contains a protein receptor 
(LAMP-2A, lysosomal-associated membrane protein-2A) that recognizes it and mediates its 
translocation into the lysosome (Dice, 2007). Then, macroautophagy (henceforth called 
simply autophagy) is the main form of autophagy and the best studied (Puyal et al., 2012). 
Originally, the term autophagy was coined by De Duve in 1963 to distinguish the 
heterophagic and autophagic functions of lysosomes (Klionsky, 2008) following Novikoff’s 
observation of lysosome-like structures containing organelles in the process of being 
degraded. De Duve called these structures autophagic vacuoles. Autophagy requires an 
intermediate multimembranous compartment, the autophagosome, which engulfs then 
sequesters portions of cytosol containing the proteins and organelles that are to be 
degraded. The mature autophagosomes then fuse with acidic compartments (late 
endosomes, lysosomes etc.) to form autolysosomes, which contain the hydrolases necessary 
for the autophagic degradation. 
Until recently, (macro)autophagy was thought to be a nonspecific mechanism, but 
evidence accumulated over the last 5-10 years indicates that autophagic adapters such as 
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p62 and NBR1 can act as cargo receptors for the selective autophagy of ubiquitinated 
substrates such as misfolded proteins, p62 bodies, aggresomes, peroxisomes, mitochondria 
and invading bacteria (Johansen and Lamark, 2011). Selective autophagy can also occur 
independently of ubiquitin (Johansen and Lamark, 2011). The selective autophagy of 
peroxisomes is called pexophagy and that of mitochondria is called mitophagy, and both of 
these events can play a role in cell death or its prevention, as is mentioned below. 
 
3.2. Summary of the molecular mechanisms of autophagy 
The progressive discovery of 31 autophagy genes (named atg: autophagic related 
genes) in yeast was crucial for the elucidation of the molecular mechanisms of autophagy. 
Several homologous genes were then identified in mammalian cells showing that autophagy 
was a strongly conserved process throughout evolution. The autophagic process can be 
divided into three main stages in which the different Atg proteins come into play with complex 
interrelationships (He and Klionsky, 2009; Simonsen and Tooze, 2009) : the induction of 
autophagy (nucleation), the formation of the autophagosome (elongation, incurvation, 
closure), and its maturation (formation of the autolysosome) (Fig. 5). 
 
3.2.1. Phase of induction 
Being an essential physiological process, autophagy is tightly regulated. It is 
maintained at a weak basal level in normal conditions, and is induced when necessary. 
Autophagy starts by the isolation of a membrane, called the pre-autophagosome, where all 
the proteins necessary for the formation of an autophagosome are recruited. In mammals, the 
origin of the pre-autophagosome has long been obscure, but recent studies showed that at 
least some autophagosomes are formed from membranes of pre-existing organelles such as 
the ER (an ER subdomain called the omegasome), the Golgi apparatus (Mari et al., 2010a; 
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Ohashi and Munro, 2010) and/or mitochondria (Axe et al., 2008; Hailey et al., 2010; Hayashi-
Nishino et al., 2009). Plasma membrane can be also a source of membrane for 
autophagosome formation (Ravikumar et al., 2010). The molecular regulators acting in this 
early phase of autophagy include a central player, the serine/threonine protein kinase mTor 
(mammalian target of rapamycin), which inhibits autophagy at two levels (Carrera, 2004). On 
the one hand it affects certain Atg proteins, such as mAtg13 (mammalian Atg13) and ULK1/2 
(UNC-51-like kinase 1/2; mammalian homologues of yeast Atg1), and thus interferes directly 
with the formation of autophagosomes (cf. below). On the other hand, mTor acts indirectly on 
the expression level of certain proteins implicated in autophagy such as LC3 (microtubule-
associated protein 1 light chain 3; homologue of yeast Atg8) and Atg14 (Reggiori and 
Klionsky, 2002). Unlike in yeast, the ULK1/2-mAtg13-FIP200 (focal adhesion kinase family-
interacting protein of 200 kD) complex appears to be stable whatever the nutritive conditions, 
but the binding of mTor to the complex depends on its activation. In pro-autophagic 
conditions as nutrient deprivation, mTor is inhibited and does not bind to the complex, with 
the result that ULK1/2 can phosphorylate and activate mAtg13 and FIP200. The ULK1/2 
complex is located at the level of the pre-autophagosome and is therefore important for the 
initial induction of the autophagy (Hosokawa et al., 2009; Jung et al., 2009). However an 
mTor-independent autophagy has also been described (Sarkar et al., 2009; Tan et al., 2012; 
Williams et al., 2008). 
In cerebral HI injury, the following deleterious events have been shown to be inducers 
of autophagy in different cell types: an increase in cytosolic calcium (Gao et al., 2008; Hoyer-
Hansen et al., 2007; Wang et al., 2008), hypoxia (Scherz-Shouval and Elazar, 2007) and 
reactive oxygen species (H2O2 and O2-) production (Chen et al., 2009; He and Klionsky, 
2009; Scherz-Shouval et al., 2007). 
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3.2.2. Phase of autophagosome formation 
During the phase of autophagosome formation, the pre-autophagosome undergoes a 
phase of elongation, followed by incurvation leading to end-to-end fusion to form a closed 
multi-membranous vesicle, the autophagosome, in which the cytoplasmic constituents to be 
degraded are sequestered. These stages depend on the interaction of different complexes in 
which the various Atg proteins play a variety of roles. The best known interactions are those 
formed by the Beclin1/PI3K-III (class III phosphatidylinositol-3 kinase) complex, the LC3 
conjugation system, the Atg12-Atg5 conjugation complex and mAtg9 (Fig. 5).  
The Beclin1/PI3K-III complex plays a role in both the induction of autophagy and in the 
formation of autophagosomes. While PI3K-I (class I phosphatidylinositol-3 kinase) is an 
inhibitor of autophagy in mammals, PI3K-III is an activator. Two Beclin1/PI3K-III complexes 
have been identified up till now in mammals (Itakura et al., 2008). Both are composed of 
PI3K-III (homologue of Vps34, vacuolar protein sorting 34, in yeast), of p150 (homologue of 
Vps15) and of Beclin1 (homologue of Atg6). Beclin1 can bind either to Atg14L (yeast Atg14-
like; also called Barkor (Sun et al., 2008c)) or to UVRAG (UV irradiation resistance-
associated gene) (Liang et al., 2006; Takahashi et al., 2009). The Beclin1/PI3K-III/Atg14L 
complex is important for the formation of the pre-autophagosome because it plays an 
essential role in the recruitment of the Atg12-Atg5 protein complex and of LC3 (Itakura et al., 
2008; Matsunaga et al., 2009; Zhong et al., 2009). Recently a domain on Atg14L has been 
identified that recruits Atg14L specifically to curved membranes enriched in PtdIns(3)P and 
involved in autophagosomes formation (Fan et al., 2011). The Beclin1/PI3K-III/UVRAG 
complex not only promotes the activation of PI3K-III via UVRAG, but also plays a role in the 
deformation and curvation of the membrane of the pre-autophagosome via the interaction of 
UVRAG with Bif-1 (Bax-interacting factor-1 or endophilin B1). Bif-1 is bound to membranes of 
different organelles (Golgi, mitochondria) and plays a role in the regulation of their dynamics 
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by its capacity to generate curvature (Takahashi et al., 2009). Furthermore, other protein 
interactions with Beclin1 have been revealed, suggesting the existence of additional 
Beclin1/PI3K-III complexes that are currently unknown. Indeed, it has been shown that 
Beclin1 can bind to Ambra1 (activating molecule in beclin1-regulated autophagy; (Fimia et 
al., 2007)) and to VMP1 (vacuole membrane protein 1; (Vaccaro et al., 2008)), two activator 
proteins of autophagy.  
The LC3 (Atg8) conjugation system controls the size of the autophagosome by its 
capacity to determine the elongation, curvature and end-to-end fusion of the pre-
autophagosome membrane (Fujita et al., 2008a; Nakatogawa et al., 2007; Sou et al., 2008; 
Xie et al., 2008). Several homologues of Atg8 exist in mammals, including the GABARAP (γ-
aminobutyric acid type A receptor-associated protein) family, and the transport factor GATE-
16 (Golgi-associated ATPase enhancer of 16kDa), but LC3 is the best studied and the most 
used for characterizing the presence of autophagy. In a manner similar to that of 
ubiquitination, LC3 is conjugated to phosphatidylethanolamine (PE), an abundant membrane 
phospholipid. LC3 first loses 22 amino acids due to the action of the cysteine protease Atg4, 
producing the cytosolic form of LC3 designated LC3-I (the first of two functions of Atg4 in this 
pathway). LC3-I is then activated by a thioester linkage to Atg7 (enzyme E1) and is then 
transferred to Atg3 (enzyme E2) by another thioester linkage. Finally, LC3-I becomes LC3-II 
through its conjugation to a phosphatidylethanolamine, causing a change of conformation 
that permits it to be incorporated in the pre-autophagosome membrane (Geng and Klionsky, 
2008). Once the autophagosome has been formed, LC3-II is removed from the external 
membrane by Atg4 which hydrolyses the link between LC3-I and its 
phosphatidylethanolamine (second function of Atg14). LC3-II remains however in the internal 
membrane of the mature autophagosome.  
 21 
 
The Atg12-Atg5-Atg16L conjugation system is essential for the elongation process, for 
the recruitment of LC3 at the pre-autophagosomal level and its conjugation to 
phosphatidylethanolamine (Fujita et al., 2008b; Longatti and Tooze, 2009; Mizushima et al., 
2001). In a manner resembling that of the LC3 conjugation system, Atg12 is conjugated to 
Atg5. Atg12 is first activated by its binding to Atg7 (enzyme E1), is then transferred to Atg10 
(enzyme E2), and is finally conjugated to Atg5 (Geng and Klionsky, 2008). Atg16L 
(homologue of Atg16) binds to the complex via Atg5, which then binds to the membrane of 
the pre-autophagosome (Mizushima et al., 2003). The Atg16L complex determines where 
LC3 will be lipidated and consequently the membrane biogenesis site. Atg12-Atg5-Atg16L 
may have an E3-like activity in the LC3 conjugation system (Fujita et al., 2008b; Romanov et 
al., 2012).  
Mammalian Atg9 (mAtg9) is an integral membrane protein required for the formation of 
the autophagosome. In mammals, mAtg9 is localized in the trans-Golgi network and in late 
endosomes but has not been observed in mitochondrial membranes as in yeast (Reggiori et 
al., 2005). A function of mAtg9 in the elongation of the pre-autophagosome is suspected 
probably by the recruitment of membrane lipids or of trans-Golgi network proteins necessary 
for the elongation stage (Orsi et al., 2012; Webber et al., 2007). Bif-1 has been shown to be 
necessary for Atg9 trafficking from Golgi to early autophagosomes (Takahashi et al., 2011). 
It has recently been proposed that autophagy can occur by alternative pathways in 
addition to the conventional one, dependent on the Atg5-Atg12 and LC3 conjugation 
systems. One such pathway was reported in Atg5-/- and Atg7-/- MEF cells, where the 
formation of autophagosomes appears to occur by the fusion of unconventional pre-
autophagosomes with vesicles from the trans-Golgi network and late endosomes (Nishida et 
al., 2009). Like the conventional pathway, this alternative one is dependent on Beclin1/PI3K-
III, but several studies have shown that Beclin1-independent autophagy can occur and can 
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moreover promote cell death in conditions of stress (Grishchuk et al., 2011; Scarlatti et al., 
2008; Zhu et al., 2007b). 
Most proteins involved in the biogenesis of autophagosomes, except LC3-II in the 
internal membrane, are removed before the complete formation of the autophagosome. 
These proteins are apparently recycled for reuse (Reggiori et al., 2004). This may explain 
why the synthesis of new proteins is not essential for the induction of autophagy and the 
formation of autophagosomes (Abeliovich et al., 2000; Lawrence and Brown, 1993). 
 
3.2.3. Phase of autophagosome maturation 
Autophagosome maturation produces a functional autolysosome. This can happen 
only after the autophagosome has been completely formed and the Atg16L and LC3-II 
complexes have been removed from the external membrane. In mammals, the maturation of 
the autophagosome into a functional degradation compartment is complex. It leads to the 
acidification of the compartment and the presence of many different hydrolases (including 
cathepsins B, D and L). The formation of the autolysosome requires the intermediate stage of 
fusion with different endosomal compartments (early endosomes, multivesicular bodies, late 
endosomes) forming amphisomes before fusion with a lysosome (Simonsen and Tooze, 
2009). Thus, proteins necessary for endocytosis play a direct or indirect role in the maturation 
of autophagosomes, including Rab7, COPI (coat protein complex I) and ESCRT (endosomal 
sorting complex required for transport) (Gutierrez et al., 2004; Razi et al., 2009; Rusten and 
Stenmark, 2009). LAMP proteins, especially LAMP-2, are also involved in the maturation of 
autophagosomes (Saftig et al., 2008). 
In addition to its function in the formation of the autophagosome, the complex 
Beclin1/PI3K-III/UVRAG may play a role in the maturation of endosomes and 
autophagosomes (Matsunaga et al., 2009). The recently discovered autophagy-inhibiting 
protein Rubicon (RUN domain and cysteine-rich domain containing, Beclin1-interacting 
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protein) can bind to the Beclin1/PI3K-III/UVRAG complex and reduce the activity of the PI3K- 
III and hence the maturation of the autophagosomes and endosomes (Matsunaga et al., 
2009; Zhong et al., 2009).  
 
3.3. Difficulties concerning the demonstration of enhanced autophagy 
Over the past ten years, there has been a great increase in the study of autophagy, in 
both physiological and pathological situations. Autophagy (stricto sensu) is due to an 
increase in both autophagosome formation and lysososomal clearing, but in numerous 
studies, the induction of autophagy was deduced on the sole grounds that the number of 
autophagosomes was increased. Such evidence is however ambiguous, because it could be 
due either to a real increase in autophagic activity (i.e. an increase in autophagic flux) or to a 
defect in lysosomal degradation, which would lead to autophagosome accumulation. Such 
incomplete analyses may explain some of the controversies concerning the roles of 
autophagy in different situations (Puyal et al., 2012; Sridhar et al., 2012). In the nervous 
system, an interesting example of such ambiguity comes from studies on chronic 
neurodegenerative diseases. In Alzheimer’s disease, morphological studies had shown 
increased numbers of autophagosomes in affected neurons, and the initial conclusions were 
in favor of an increase in autophagy that could be involved in the development of the disease 
(Cataldo et al., 1995; Cataldo et al., 1996). But recent studies have clearly demonstrated that 
this autophagosome increase is not due to an increase in autophagy but to a decrease in 
lysosomal degradation (Lee et al., 2010; Nixon and Yang, 2011), and the restoration of 
lysosomal function in animal models of Alzheimer’s disease have been found to restore 
neuronal function and increase cognitive performance (Yang et al., 2011). 
For these reasons explained above, the involvement of autophagy stricto sensu in a 
particular situation needs to be demonstrated by monitoring not only autophagosome 
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formation but the whole process of autophagy, i.e. the autophagic flux (Klionsky and 1269 
others, 2012). 
 
3.4 The term “autophagic cell death” 
There has been controversy, as is discussed below, concerning the importance, and 
even the existence, of “autophagic cell death” (Clarke and Puyal, 2012; Kroemer and Levine, 
2008; Puyal et al., 2012; Yuan and Kroemer, 2010). Part of the controversy has been due to 
confusion related to changes in the meaning of this term. It was coined in the 1970s in a 
purely morphological context to refer to dying cells that contained numerous autolysosomes 
(and sometimes autophagosomes) and lacked the characteristics of other types of cell death 
(Clarke, 1990). Based on this morphological observation, it was supposed that in some 
conditions autophagy could be implicated in promoting cell death, because the 
autolysosomes often contained more than half the cytoplasm, and sometimes even parts of 
the nucleus including some of its DNA (Clarke, 1990; Hornung et al., 1989). Nevertheless, 
death-mediation was not strictly part of the original definition. 
Confusingly, the term “autophagic cell death” is now used in at least three different 
ways: 1) autophagy-associated cell death (the original definition), 2) autophagy-mediated cell 
death (which might involve a standard mechanism of cell death triggered by autophagy, 
because strongly autophagic dying cells sometimes also show characteristics of apoptosis 
and/or necrosis), and 3) a distinct mechanism of cell death, independent of apoptosis or 
necrosis (Fig. 6). We shall use the term “autophagic cell death” in this third sense, in 
conformity with most (Clarke et al., 2008; Elgendy et al., 2011; Galluzzi et al., 2012; Shen 
and Codogno, 2011) but not all (Uchiyama et al., 2009) recent usage. Thus, to qualify as 
“autophagic” the cell death must show greatly enhanced autophagic flux, the autophagy must 
be death-promoting, and the cell death must not be apoptotic or necrotic. For in vivo studies 
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of mammalian neurons, it is hard to measure autophagic flux directly, but the presence of 
greatly increased numbers of autolysosomes (not just autophagosomes) would be a useful 
indication. To prove a death-mediating role of autophagy can be difficult, because cells 
(especially mammalian cells) often respond to the inhibition of one death pathway by 
activating an alternative one. Therefore, a cell that was genuinely dying by autophagic cell 
death might still die, but by apoptosis or necrosis, if tested with an inhibitor of autophagy. For 
this reason, we think that cell death showing strongly enhanced autophagy and no sign of 
apoptosis or necrosis should be considered “autophagic” if autophagy inhibition delays the 
death, even if the cells ultimately die by apoptosis or necrosis.  
 
3.5.  Autophagy in the mediation of cell death 
As discussed above, two different questions have to be asked about situations where 
autophagy is enhanced in the presence of cell death: 1) Is the cell death autophagy-
mediated, or is the induction of autophagy playing some other role, perhaps as an ultimate 
reaction to protect the cell? 2) If the cell death is indeed autophagy-mediated, does it qualify 
as true autophagic cell death in the strict sense described above. 
To demonstrate a death-mediating role of autophagy, the universal strategy has been 
to show that its inhibition reduces (or at least delays) the cell death (Lenardo et al., 2009). 
Early studies suggesting a death-mediating role of autophagy relied on pharmacological PI3K 
inhibitors, notably 3-methyladenine (3-MA) (Seglen and Gordon, 1982) and sometimes 
wortmaninn or LY294002, (Blommaart et al., 1997). These inhibitors prevent autophagy, 
because they inhibit PI3K-III, which is essential for most autophagy. 3-MA and other PI3K 
inhibitors attenuate or prevent autophagy-associated cell death in numerous situations, e.g. 
following nerve growth factor deprivation of sympathetic neurons (Xue et al., 1999), serum 
deprivation of PC12 cells (Guillon-Munos et al., 2005) or hypoxia of different cancer cell lines 
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(Azad et al., 2008). However, in view of the incomplete specificity of the inhibitors, notably by 
their probable pro-apoptotic action on PI3K-I, or by different temporal patterns of inhibition for 
PI3K-I and PI3K-III (Wu et al., 2010), it has been necessary to clarify the relationship 
between autophagy and cell death by more specific techniques, notably the genetic inhibition 
of Atg proteins. 
The first molecular genetic evidence for a death-mediating role of autophagy came 
from two studies showing that cells incapable of activating the mechanisms of apoptosis 
could die by an autophagic form of death. In one of these studies, general inhibition of 
caspases or specific inhibition of caspase-8, in different cell lines or in macrophages, induced 
nonapoptotic cell death involving the presence of multiple autophagosomes. This death was 
blocked by the inhibition of Beclin1 or of Atg7 by RNA interference (Yu et al., 2004). It was 
later shown that this type of death induced by caspase inhibition led to an accumulation of 
reactive oxygen species following the selective autophagic degradation of catalase, probably 
through pexophagy (Yu et al., 2006a). In the other study, MEF cells from bax/bak deficient 
mice or MEF cells overexpressing Bcl2/BclXL contained numerous autophagosomes after 
treatment with certain apoptotic stimuli. Their death could be prevented not only by treatment 
with 3-MA or wortmaninn, but also by diminishing the expression of Beclin1 or of Atg5 by 
RNA interference (Shimizu et al., 2004). These results provided strong support for a death-
mediating role of autophagy, but other studies showed that when autophagy was induced in 
the very same bax-/-/bak-/- MEF cells by amino acid deprivation, its inhibition by 3-MA was 
death-promoting rather than being protective (Tsujimoto and Shimizu, 2005). The role of 
autophagy is then highly dependent notably on the cell type and the nature of the stimulus. 
The studies of Yu et al. (Yu et al., 2004) and Shimizu et al. (Shimizu et al., 2004) showed that 
autophagy can be a mediator of cell death in cultured cells whose apoptotic machinery was 
inactivated, suggesting a death role for autophagy as an alternative to apoptosis. But there is 
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other evidence that autophagy can promote cell death by triggering apoptosis (see below) as 
when Atg1 is overexpressed in Drosophila inducing autophagy that leads to cell death with 
an apoptotic morphology and caspase activation (Scott et al., 2007).  
On the other hand, autophagy can mediate cell death independently of apoptosis in 
cells that are apoptosis-competent. In various cancer cell lines, hypoxia induces a death that 
is not affected by the presence of a caspase inhibitor (z-VAD-fmk) but is strongly reduced by 
RNA interference of Atg5 or of Beclin1 (Azad et al., 2008). Similar results were obtained 
when the death was induced by oxidative stress due to the addition of H2O2 on cell lines 
(Chen et al., 2008). Adult hippocampal neural stem cells that were dying because of insulin 
withdrawal showed morphological and biochemical characteristics of enhanced autophagy, 
leading to an apoptosis-independent cell death (Baek et al., 2009; Yu et al., 2008). In these 
cells, autophagy inhibition by Atg7 knockdown was demonstrated to be protective and 
autophagy stimulation using rapamycin increased cell death. This work demonstrated that 
autophagy-mediated cell death could occur in apoptosis-competent stressed neurons without 
the involvement of apoptosis.  
Dictyostelium cells are an interesting in vitro model to study autophagic cell death 
because they lack apoptotic pathways (Giusti et al., 2010), and show the complexity of the 
roles that enhanced autophagy could play depending on the conditions. When starved and in 
presence of cAMP, Dictyostelium cells induced autophagy as a survival response, but once 
they had been sensitized by this first stress, a second signal (the differentiation factor DIF-1) 
converted the enhanced autophagy into a destructive mechanism (Luciani et al., 2011). This 
suggests that autophagic cell death may require two successive signals, of which the first 
enhances autophagy and sensitizes the cells to the second one.  
Another excellent example is the cell death that occurs during the metamorphosis of 
Drosophila. Whereas the salivary glands disappear during this period by a combination of 
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autophagy and apoptosis (Berry and Baehrecke, 2007), the elimination of the midgut results 
from a caspase-independent cell death that requires the activation of autophagy (Denton et 
al., 2009). Thus, RNA interference knockdown of caspases has no effect on the midgut 
elimination but knockdown of Atg1 or Atg18 greatly delays the cell death. It also tends to 
increase caspase activity, but the knockdown of both caspases and autophagy in parallel 
does not cause an additional effect, implying a primary role for autophagy but not caspases 
in the death process. This study is to date the most convincing line of evidence for the 
existence of autophagic cell death in a natural situation. 
   
3.6. Autophagy in excitotoxicity and cerebral ischemia  
Autophagy has been shown to be present in dying neurons in various models of 
excitotoxicity both in vitro and in vivo: hippocampal slices exposed to NMDA (Borsello et al., 
2003), the long term exposure of organotypic cultures of lumbar spinal cord to an inhibitor of 
glutamate transporters (Matyja et al., 2005), the direct in vivo injection of kainate into the 
brains of mice (Shacka et al., 2007) or into the spinal cord (Kanno et al., 2009), and traumatic 
brain injuries (Luo et al., 2011).  
The first study showing an activation of autophagy after cerebral ischemia was that of 
Nitatori et al. in 1995 who demonstrated ultrastucturally the presence of numerous 
autophagic vacuoles and an increase in the size of cathepsin B positive vesicles in 
hippocampal CA1 neurons 3 days after ischemia (Nitatori et al., 1995; Nitatori et al., 1996). 
Later studies on adult cerebral ischemia and neonatal HI showed increases in the activation 
and expression of lysosomal proteases (Seyfried et al., 1997; Wen et al., 2008), found an 
increased expression of autophagosomal marker LC3-II by Western blot (Degterev et al., 
2005; Ginet et al., 2009; Puyal et al., 2009; Zhu et al., 2005) and showed increased numbers 
of autophagosomes and autolysosomes by electron microscopy (Adhami et al., 2006; Ginet 
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et al., 2009; Puyal et al., 2009). Enhanced autophagy has also been demonstrated in a 
retinal ischemia model (Piras et al., 2011). Recently, in vivo imaging through the skull of 
GFP-LC3 transgenic mice showed a peak in fluorescent signal in the ischemic hemisphere 
24h after transient MCAO (Tian et al., 2010). 
The role of this induction of autophagy was first studied in vivo in a model involving the 
intra-striatal injection of kainate; injection of 3-MA or an inhibitor of cathepsin B was shown to 
reduce the size of the lesion, even when performed 3h post-kainate (Wang et al., 2006; 
Wang et al., 2008). Similar results were obtained in a model involving MCAo when similar 
inhibitors were injected at the beginning of ischemia (Wen et al., 2008). In a severe neonatal 
(12 day old) model of cerebral ischemia, 3-MA was also strongly neuroprotective, reducing 
the lesion volume by almost 50% when given as late as 4.5 h after the onset of ischemia. In 
contrast, caspase inhibition (with Q-VD-OPh or Z-VAD-fmk) provided no protection (Puyal et 
al., 2009). However, an opposite role for enhanced autophagy has been proposed by Carloni 
and colleagues in neonatal HI since in their model 3-MA had no effect on brain lesion 
whereas rapamycin was protective (Carloni et al., 2008). However they used a very weak 
dose of 3-MA, and its effect on autophagy was checked only indirectly, by measuring Beclin1 
expression, never by a direct marker such as LC3-II. 
A problem with all the above studies is that 3-MA and rapamycin have limited 
specificity for the modulation of autophagy (Hughes and Kennedy, 2012; Wu et al., 2010), so 
confirmation was needed with more specific, molecular methodologies. An important study 
(Koike et al., 2008) in neonatal conditional knockout mice with neuron-specific deletion of 
Atg7 showed that the absence of autophagy led to resistance against HI in the hippocampus, 
providing the strongest evidence so far for a death-mediating role of autophagy in hypoxic-
ischemic neurons. Such a study is impossible in adult models due to the essential role of 
basal autophagy and the neurodegeneration that occurs in the knockout mice from 3 weeks 
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of age (Komatsu et al., 2006; Komatsu et al., 2007). More recently, it has been shown that 
the downregulation of Beclin1 by lentiviral delivery of shRNA into the thalamus of adult rats 
decreased the neuronal death that occurs there secondarily to cerebral (mainly cortical) 
infarction following distal MCAo. In this experiment the MCAo affected the thalamic neurons 
only indirectly, because of their connections with the cortex (Xing et al., 2012).  
In conclusion, there is compelling evidence for a death-mediating role of enhanced 
autophagy in experimental excitotoxicity, cerebral hypoxia-ischemia and stroke, in both adult 
and immature brains (Puyal et al., 2012). In many cases the autophagy triggers apoptosis, as 
is discussed further in section 6.2., but in some cases the cell death may be “autophagic” in 
the strict sense. 
 
4. Cell death of type 3 - necrotic 
4.1. Morphological definition of type 3 cell death  
Type 3 cell death was initially defined in the context of normal development 
(Schweichel and Merker, 1973), whereas necrosis (also called coagulative necrosis by 
pathologists) was initially considered to occur only in severely damaged tissues (Wyllie et al., 
1980), but the two types resemble each other morphologically, and are now generally 
considered to be variants of a single type of cell death.  
In the context of development, type 3 cell death was divided into two main variants, 3A 
and 3B (Clarke, 1990), but we here ignore type 3A because it is rare and has never been 
reported in the nervous system. Type 3B is also referred to as the cytoplasmic type of cell 
death (Pilar and Landmesser, 1976), or paraptosis (Sperandio et al., 2000). Most 
morphological studies of type 3B cell death have been in developing neurons; it is 
characterized particularly by dilation of the organelles and of the perinuclear space and by a 
vacuolization of the cytoplasm. The nucleus is relatively unaffected, but finally swells and is 
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lysed, and the cell is ultimately phagocytozed (Clarke, 1990; Clarke, 1999) (Fig. 1). The 
biochemical pathways of this kind of cell death are not well understood. There has been 
some recent progress in cell lines, but the relevance of this our present focus on 
excitotoxicity in neurons is unclear (Sperandio et al., 2010). We therefore focus the present 
discussion on necrosis. 
Necrosis resembles types 3A and 3B to the extent that it is characterized by 
vacuolization (Fig. 2D), due primarily to organelle dilation, but the changes are more dramatic 
and necrotic cells are invariably very swollen, in both cytoplasm and nucleus. In the 
cytoplasm, there is initially a gross dilation of mitochondria, whose cristae break, and then of 
the ER, which fragments into vesicles. The nucleus also swells, and its heterochromatin 
becomes coarser, forming discrete masses on the nuclear membrane, before its dissolution, 
which leaves a nuclear “ghost” (Majno and Joris, 1995; Wyllie et al., 1980). Many authors 
have claimed that the cellular swelling causes such tension in the plasma membrane that it 
breaks, and that this is the cause of the cell death (Majno and Joris, 1995; Rothman, 1985). 
This may be true in some situations, but this is no longer believed to be the main cause of 
necrotic cell death, at least not in vivo (Clarke, 1999). There are no specific biochemical 
markers of necrosis, although markers of calpain activation may be suggestive of it in certain 
contexts, as we shall discuss. Labeling by vital dyes to show permeabilization of the plasma 
membrane can likewise be suggestive of necrosis, but only electron microscopy can 
demonstrate this type of cell death definitively. 
 Necrosis was originally considered to be a purely passive and uncontrolled type of 
cell death, and it is true that it often occurs in situations of energy failure where energy-
dependent mechanisms such as caspase-activation and autophagy cannot occur (Golstein 
and Kroemer, 2007; Kitanaka and Kuchino, 1999), but there is nevertheless evidence that 
necrosis can be regulated and for this reason some authors refer to “programmed necrosis” 
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to emphasize that signaling pathways are involved (Edinger and Thompson, 2004; Galluzzi et 
al., 2011). Nevertheless, current understanding of these signaling pathways is rather limited. 
In many cases, including those of most relevance to this review, necrotic cell death is initiated 
by a substantial rise in cytosolic calcium, which then leads to cell death through various 
calcium-dependent pathways. Some of these involve the activation of calpains, as is 
discussed below. In other cases, (programmed) necrosis is initiated by the activation of death 
receptors, in which case it is usually termed necroptosis (Galluzzi et al., 2011). Necroptosis is 
caspase-independent and can occur in apoptosis-incompetent cells. It is activated by the 
receptor-interacting protein 1 (RIP1), which is a kinase and sometimes called RIP1-kinase or 
RIP1K. Cells can be protected against necroptosis by necrostatin-1, a specific inhibitor of 
RIP1 (Galluzzi et al., 2011). Other members of the RIP-kinase family may also be involved in 
necroptosis, and a whole family of necrostatins are currently being characterized (Degterev 
et al., 2008; Smith and Yellon, 2011). The promise of this research for neuroprotection 
against cerebral ischemia seems considerable, as is discussed in the next section. 
 
4.2. Neuronal necrosis in excitotoxicity and cerebral ischemia 
Excitotoxicity and cerebral ischemia frequently involve necrosis, and a major cause of 
it is the massive influx of calcium that occurs mainly through voltage-dependent channels 
following cellular depolarization (Hou and MacManus, 2002). The intensity of glutamate 
exposure and the subsequent loss of membrane potential are key players in necrosis 
(Ankarcrona et al., 1995). Thus, it is induced rapidly in both excitotoxicity (Arthur et al., 2007) 
and in cerebral ischemia (Ueda, 2004). In focal cerebral ischemia, neuronal death occurs 
most massively and rapidly in the “core” of the ischemic region, where the ischemia is almost 
total and the energy deprivation severe, and this is the site where neuronal necrosis 
predominates (Hou and MacManus, 2002) (Fig. 3D). The duration of ischemia and the 
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amplitude of reperfusion are among the parameters determining the core area. Necrotic cell 
death mechanisms have a more significant role in adult models since immature neurons are 
very sensitive to apoptosis (Liu et al., 2004; Zhu et al., 2005; Zhu et al., 2003). However, in 
neonatal cerebral hypoxia-ischemia necrosis likewise occurs rapidly (Nakajima et al., 2000; 
Northington et al., 2001a; Northington et al., 2001b) and contributes importantly to the 
cerebral lesion (Carloni et al., 2007; Towfighi et al., 1995). 
In most cases of excitotoxicity and in cerebral ischemia, the main stimulus to neuronal 
necrosis is a rise in intracellular calcium due largely to calcium entry through NMDA 
channels. In view of the importance of calcium in the mediation of necrotic cell death, several 
studies of cerebral ischemia and cerebral HI have investigated the roles of calpains, which 
are a class of cytosolic cystein proteases that are activated by raised calcium and are known 
to be involved in the mediation of necrotic cell death. Calpains degrade many essential 
proteins including α-fodrin, which is a cytoskeletal protein. They cleave it specifically to give a 
fragment of 150 kDa that can be identified in Western blots. Numerous authors have used 
this specific fodrin cleavage as a marker to evaluate the activation of calpains in response to 
an ischemic or HI insult (Zhu et al., 2005), and have investigated the neuroprotective effects 
of calpain inhibitors. The interpretation of these results is complicated by the fact that 
calpains can also be activated in non-necrotic forms of cell death, for example by caspase-12 
during apoptosis (Nakagawa and Yuan, 2000), or can mediate excitotoxic apoptosis (Orsi et 
al., 2012). 
Nevertheless, in view of the difficulty of analyzing necrotic death mechanisms by other 
biochemical approaches, the studies of calpains provide some of the most valuable evidence 
about necrotic mechanisms in the brain, especially when morphological studies confirm that 
necrotic cell death is indeed occurring. In adult focal cerebral ischemia and neonatal hypoxia-
ischemia, calpain-specific cleavage of α-fodrin occurs (Han et al., 2002; Zhu et al., 2005), as 
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expected, rapidly in the core and somewhat later in the peri-infarct region, preceding the 
neuronal death (Kambe et al., 2005). Furthermore, calpain inhibitors have been found in 
many studies to be neuroprotective against the ischemia (Kambe et al., 2005), and in view of 
the long therapeutic window of up to six hours found in animal models (Markgraf et al., 1998) 
they may have clinical potential.  
Necroptosis is a form of programmed necrosis dependent on the serine–threonine 
kinase RIP1 and necrostatin-1 has been identified as a selective inhibitor of RIP1 which does 
not affect caspase activation (Degterev et al., 2005; Degterev et al., 2008). It has been 
shown that retinal and cerebral ischemia involves necroptosis (Degterev et al., 2008; 
Rosenbaum et al., 2010). Administration of necrostatin-1 afforded neuroprotection against 
MCAo in mice even when injected 6h after the insult, whereas zVAD-fmk was no longer 
efficient at this time point (Degterev et al., 2008). In neonatal mice, post-treatment with 
necrostatin-1 also gave neuroprotection against HI (Northington et al., 2011). These results 
showed that necroptosis is an important delayed mechanism of ischemic brain damage and 
could be an important therapeutic target. 
In excitotoxicity and cerebral ischemia pathological activation of Poly(ADP-Ribose) 
Polymerase (PARP) occurs and contributes to necrotic cell death mainly via cytosolic NAD+ 
depletion (Alano et al., 2010; Moroni, 2008). PARP inhibition or deletion of PARP-1, which is 
the member of PARP family responsible for more than 90% of cellular PARP activity, is then 
strongly neuroprotective (Endres et al., 1997; Kaundal et al., 2006; Nakajima et al., 2005) – 
especially in males (see section 5.2.). PARP appears to be involved in both passive and 
active varieties of necrosis. Its primary role is to detect single-strand DNA breaks and initiate 
repair, but its excessive activation is a powerful stimulus for cell death. Extreme PARP-
activation can deplete a cell’s nicotinamide adenine dinucleotide and consequently its ATP to 
such an extent that it causes necrosis of the standard, passive kind, while inhibiting energy-
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dependent types of cell death such as apoptosis (Ha and Snyder, 1999; Kaundal et al., 
2006). But PARP can also induce caspase-independent active cell death, via the production 
of poly(ADP-ribose) polymer (PAR), which translocates from the nucleus to the cytosol where 
it interacts with the mitochondrial outer surface and stimulates AIF release (Fig. 7) (Wang et 
al., 2011; Yu et al., 2006b). Even though most AIF-induced cell death is apoptotic (section 
2.2.2.) in situations of strong PARP activation it takes on a different morphology and recent 
papers argue that it is a distinct form of cell death, termed parthanatos (Wang et al., 2009b), 
which is arguably a form of programmed necrosis (Galluzzi et al., 2012). The difference 
between AIF-induced apoptosis and parthanatos appears to result from a binding of PAR to 
AIF (Wang et al., 2011). 
 
5. Parameters influencing the cell death mechanisms involved in cerebral hypoxic-
ischemic damage  
5.1. Brain maturity  
The age at which hypoxia-ischemia is performed is another important parameter 
affecting the severity of the lesion (Towfighi et al., 1997). The conclusions of studies on 
neuroprotection in adult models of cerebral ischemia cannot be transposed to the neonatal 
situation without further confirmation, because the different physiological and metabolic 
properties of immature brains lead to different molecular consequences. For example, the 
basal activity of caspase-3 is much higher in immature brains than in those of adults, making 
them more sensitive to the induction of apoptosis (Zhu et al., 2005; Zhu et al., 2003). Hence, 
unlike in adults, HI in neonatal rats activates apoptotic mechanisms within only a few hours 
(Nakajima et al., 2000; Northington et al., 2001a; Zhu et al., 2005). 
 Another age-related difference is that the subunits of NMDA receptors change during 
development and they become more heterogeneous. Immature brains express mainly 
subunits NR1, NR2B and NR2D, but very few NR2A in comparison with adults (Gurd et al., 
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2002; Johnston, 2005; Mishra et al., 2001; Wenzel et al., 1997). Thus the immature NMDA 
receptors have different properties from those in adults. Their permeability to Ca2+ is higher, 
they are more readily activated by glycine, and they are less sensitive to blockade with Mg2+. 
These properties all make immature NMDA receptors more readily activatable, which plays a 
positive role in many processes during brain development (establishment of neural 
connections, neuronal migration and long term potentiation) but increases the vulnerability to 
hypoxia-ischemia. AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors 
likewise change during the course of development, in both their composition and in their 
localization (Simeone et al., 2004). Expression of the GluR2 subunit, which confers 
impermeability to Ca2+, increases with age in rodents. For this reason, immature brains 
express a higher proportion of calcium-permeable AMPA receptors, enhancing their 
sensitivity to excitotoxicity. This may help to explain the switch in vulnerability to 
excitotoxicity, during the first week of life, from white matter to gray matter (Talos et al., 
2006). Thus, in 2-day old rats, calcium-permeable AMPA receptors are mainly expressed in 
the white matter (on radial glia and oligodendrocyte precursors), which is particularly 
vulnerable. But at 7 days, the calcium-permeable receptors are mainly on cortical neurons, 
and at this age the gray matter is more vulnerable (Talos et al., 2006). Another factor that 
exacerbates the vulnerability of immature brains is that GABA receptors, which are inhibitory 
in adults, are excitatory (depolarising) during the first two weeks of life in rodents (Ben-Ari et 
al., 1997; Jensen, 2002). Immature brains are also particularly vulnerable to oxidative stress 
because their antioxidant defences are week, and they contain high concentrations of free 
iron and unsaturated fatty acids (Vannucci and Hagberg, 2004). 
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5.2. Gender differences 
Both human and animal studies have revealed a sexual dimorphism in adult and 
neonatal cerebral ischemia (Alkayed et al., 1998; Hurn et al., 2005; Turtzo et al., 2011; Turtzo 
and McCullough, 2010; Vagnerova et al., 2008). The overall incidence rate of stroke is higher 
in men than in women. However stroke risk depends on the age group studied since in some 
periods of life (20-35, 44-55, >85 years) women are more likely to suffer cerebral ischemia 
(Turtzo and McCullough, 2010). Sex hormone exposure is an important factor and female 
rats are more resistance to MCAo than males or ovariectomized females of the same age 
(Alkayed et al., 1998). However, hormonal factors are not the only cause of sex differences; 
strictly genetic parameters also play a role (Siegel et al., 2010; Turtzo et al., 2011; Turtzo and 
McCullough, 2010) and sexual dimorphism could be observed even in in vitro models of 
excitotoxicity (Du et al., 2004; Fairbanks et al., 2012; Li et al., 2005; Sharma et al., 2011). 
Most studies indicate that cell death in females occurs mainly via a caspase-dependent 
pathway whereas in males AIF translocation and PARP-1 activation are more important 
players (Lang and McCullough, 2008; Renolleau et al., 2008; Zhu et al., 2006). Only females 
presented a rapid release of cytochrome c with enhanced caspases activation and were 
protected by caspase inhibition following Q-VD-OPh administration, in both adult and 
neonatal rodent models of cerebral ischemia (Liu et al., 2009; Liu et al., 2011; Renolleau et 
al., 2007). Deletion of the gene coding for PARP-1 reduced the lesion size in neonatal and 
adult males, but had no effect in neonatal females after HI (Hagberg et al., 2004) and even 
exacerbated stroke damage in adult females (Liu et al., 2011; McCullough et al., 2005). Other 
studies of neuroprotection have revealed additional differences between males and females 
in neonatal (Bona et al., 1998; Hill et al., 2011; Igarashi et al., 2001; Nijboer et al., 2007; Wen 
et al., 2006) or adult (Li and McCullough, 2009; Siegel et al., 2011) models, underlining the 
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importance of gender for the design of neuroprotective agents against hypoxic-ischemic brain 
damage in adults and infants. 
 
6. Interconnections between the different types of cell death  
6.1. Interconnections between necrosis and apoptosis 
Necrosis and apoptosis can share common initial events such as Fas activation 
(Kawahara et al., 1998) or mitochondrial permeabilization (Baines, 2011). A cell’s decision to 
die by apoptosis or necrosis can be dependent on different factors including its capacity for 
caspase activation (Hartmann et al., 2001; Lemaire et al., 1998; Prabhakaran et al., 2004), 
production level of reactive oxygen species (Kalai et al., 2002) and the degree of lysosomal 
membrane disruption (Brunk et al., 1997), but the level of ATP seems to be a crucial 
determinant since the induction of apoptosis requires energy, whereas necrosis often occurs 
in states of energy/ATP depletion (Leist et al., 1997). 
The existence of common mediators for apoptosis and necrosis can produce 
intermediate forms of cell death especially in neurons. In the context of excitotoxicity and 
cerebral ischemia, it was proposed, on the basis of ultrastructural evidence, that there is a 
continuum between apoptosis and necrosis in the brains of both immature and adult rats 
(Martin et al., 1998; Portera-Cailliau et al., 1997). Similar conclusions were reached at about 
the same time using different techniques on cultured neurons (Cheung et al., 1998). The 
continuum view conceives of the pure forms of apoptosis and necrosis as being at the two 
extremes of a spectrum of hybrid morphologies. This implies that the pathways of apoptosis 
and necrosis are not mutually exclusive, but can be activated together, although the extent to 
which this occurs depends on the type and maturity of the neurons. 
Hybrid morphologies have been reported in animals of all ages including adults (Wei 
et al., 2004), but occur more readily during development, and it is difficult to find classic 
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ultrastructural morphologies of pure neuronal apoptosis or necrosis in neonatal models such 
as the HI model of Rice and Vannucci (Rice et al., 1981). Using this model, several studies 
have shown the predominance of hybrid morphologies in various brain regions in neonatal 
rats and mice (Nakajima et al., 2000; Sheldon et al., 2001). It has been proposed that the 
presence of hybrid morphologies may result from the incomplete execution of apoptosis in 
neurons that therefore make an incomplete transition to necrosis (Northington et al., 2007). 
Why hybrid forms occur in some situations but pure apoptotic or necrotic forms in 
others is only partly understood. The situation is complicated, because there is evidence in a 
variety of neuronal and non-neuronal cell types for both positive and negative cross-talk 
between the apoptotic and necrotic pathways. We here limit discussion to neurons, 
emphasizing apoptotic-necrotic cross-talk in cerebral ischemia and excitotoxicity. For reasons 
discussed above, we take caspase activation as emblematic of apoptosis and calpain 
activation as emblematic of necrosis, although this is a simplification. But there is cross-talk 
between caspase and calpain signaling, and the two groups of proteases share many of the 
same substrates (Schwab et al., 2002; Wang, 2000). 
Caspase activation leads to the cleavage of many different proteins, in addition to 
those involved in the pro-apoptotic pathways, and it has both pro- and anti-necrotic effects. In 
some cases the pro-necrotic effects predominate, and, in a model of focal cerebral ischemia-
reperfusion, inhibition of caspase-3 was found to diminish the ischemia-induced activation of 
mu- and m-calpains, possibly due, at least partly, to a concurrent increase in the level of the 
calpain inhibitor calpastatin (Sun et al., 2008b). The mechanism of this positive cross-talk is 
only partly understood, but one of the direct pro-necrotic effects of caspase action is that they 
cleave plasma membrane calcium pumps leading to calcium overload, which promotes 
necrosis (Schwab et al., 2002). But caspases also have anti-necrotic effects, and one of 
these is due to the caspase-mediated degradation of AMPA receptor subunits (Glazner et al., 
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2000). AMPA receptor activation tends to induce necrosis rather than apoptosis, so the 
elimination of AMPA receptors tends to reduce necrosis and promote pure apoptosis.  
Conversely, the activation of calpains has pro- and anti-apoptotic effects. In focal 
cerebral ischemia-reperfusion, calpain inhibition was found to diminish the ischemia-induced 
activation of caspase-3 in the core (but not in the penumbra) (Sun et al., 2008b). It would be 
beyond our present scope to discuss in detail the numerous effects of calpains on apoptotic 
pathways, but these are summarized by Sun et al. (2008) who mention that calpains can 
cleave caspases 3, 7, 8, 9 and 12, as well as several apoptosis regulatory proteins including 
apoptosis protease-activating factor-1, Bcl-xL, Bax, Bid and p53, with both positive and 
negative effects on the apoptotic cascade (Sun et al., 2008b). In neonatal hypoxia-ischemia, 
the same damaged neurons could express both cleaved caspase-3 and calpain-dependent 
fodrin breakdown product, and the early activation of m-calpains appears to have contributed 
to the subsequent activation of caspase-3 in the second phase of the neuronal death 
(Blomgren et al., 2001). 
 
6.2. Interconnections between autophagy and apoptosis  
Some cases of autophagy-mediated cell death are caspase-independent and clearly 
different from apoptosis, but a mixed form with both autophagic and apoptotic characteristics 
is sometimes found (Zakeri et al., 1995). This is not surprising, because the autophagic and 
apoptotic pathways share common mediators and are interconnected (Eisenberg-Lerner et 
al., 2009; Maiuri et al., 2007).  
Several molecules known to belong to the apoptotic pathway may be also involved in 
autophagy regulation. Bcl2 is both an anti-apoptotic protein and an inhibitor of autophagy. In 
fact, the autophagy protein Beclin1 was initially identified as a protein interacting with Bcl2 via 
its BH3 domain. In conditions of stress such as lack of nutrients, Beclin1 is detached from 
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Bcl2 permitting the induction of autophagy (Pattingre et al., 2005). Thus, Bcl2 can inhibit the 
pro-autophagic effect of Beclin1 by sequestering it. This effect is not, however, reciprocal, 
because the overexpression of Beclin1 does not modify the anti-apoptotic effect of Bcl2 
(Ciechomska et al., 2009). The dissociation of Beclin1 from Bcl2 or BclXL has been shown to 
be regulated proapoptotically by the death-associated protein kinase (DAPK) (Zalckvar et al., 
2009b; Zalckvar et al., 2009a). The proapoptotic BH3-only protein Bim can also be an 
autophagy inhibitor by its interaction with Beclin1 (Luo et al., 2012) (Luo et al., 2012). In 
some cases caspases activation can lead to Beclin1 cleavage and inhibition of Beclin-
dependent autophagy (Djavaheri-Mergny et al., 2010; Luo and Rubinsztein, 2010). Like Bcl2 
and BclXL, MCL-1 has recently been shown to be an important regulator of both apoptosis 
and autophagy in cell lines and post-mitotic neurons (Germain et al., 2011). FLIP proteins are 
also not only anti-apoptotic but are also anti-autophagic because they inhibit the action of 
Atg3 and prevent the lipidation of LC3 in different cell lines (Lee et al., 2009). The 
overexpression of PUMA or Bax, two members of the Bcl2 family, in different cell lines can 
contribute to the induction of autophagy and particularly of mitophagy which, in turn, is 
associated with induction of the apoptosis (Yee et al., 2009). However, mitophagy of 
dysfunctional mitochondria can reduce apoptosis, presumably by preventing the release of 
cytochrome c and other proapoptotic factors (Kim et al., 2007). Overexpression of a nuclear 
FoxO1 (Forkhead box protein O1) can initiate caspase-dependent apoptosis, whereas 
cytosolic FoxO1 induces an autophagy-mediated cell death independently of caspases (Zhao 
et al., 2010).  
Conversely some autophagic proteins have been shown to interact with the apoptotic 
process. Atg5 can also induce apoptosis independently of its action on autophagy (Luo and 
Rubinsztein, 2007). First, in HeLa cells treated with interferon-γ (IFNγ), Atg5 can interact with 
FADD (Fas-Associated Protein with Death Domain) and thus activate caspase-dependent 
 42 
 
cell death (Pyo et al., 2005). Second, in response to various apoptotic stimuli, Atg5 can be 
cleaved by calpains in different cell lines and one of its cleavage fragments is translocated to 
mitochondria where it interacts with Bcl-xL, thus contributing to the initiation of the 
mitochondrial pathway of apoptosis (Yousefi et al., 2006). More recently it has been 
proposed that autophagosomal membrane could be a platform to recruit, via Atg5, an 
intracellular DISC which induces caspase-8 activation (Young et al., 2012). Atg4D can also 
be pro-apoptotic independently of its autophagy function; an Atg4D fragment is recruited to 
mitochondria and can induce the apoptotic mitochondrial pathway (Betin and Lane, 2009). 
Overexpression of Atg1 in Drosophila leads to a form of cell death that is both caspase and 
autophagy dependent (Scott et al., 2007). Recently it has been shown that Atg7 can control 
p53 functions in both the cell cycle and in cell death (Lee et al., 2012). 
 Links between apoptosis and autophagy have also been found in neurons. Activation 
of p53 probably participates in excitotoxic neuronal death through both apoptotic and 
autophagic pathways (Dong et al., 2012; Wang et al., 2009a; Zhang et al., 2009). In a study 
of photoreceptors (in vivo and in a photoreceptor cell line), oxidative stress was shown to 
induce autophagy and caspase-dependent apoptosis. The contribution of autophagy to the 
apoptosis was shown in the cell line by the fact that 3-MA treatment or RNA-silencing of 
Beclin1 and Atg5 diminished the caspase activation and the cell death. A caspase inhibitor 
(zVAD-fmk) also gave partial protection, but the combination of 3-MA and z-VAD-fmk gave 
no additional protection, suggesting that both were acting on the same cell death pathway. 
Taken together, these results indicated that the oxidative stress first induced autophagy, 
which in turn triggered the caspase-dependent apoptosis (Kunchithapautham and Rohrer, 
2007).  
Autophagy can also be involved in the induction of a caspase-independent neuronal 
apoptosis. Deprivation of serum and potassium triggers the death of cultured cerebellar 
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granule neurons, which shows autophagic features and enhanced intralysosomal expression 
of cathepsin L. Inhibition of cathepsin L is more strongly protective (40%) than caspase-3 
inhibition (31%), but combination of the two inhibitors is still more protective (80%). Moreover, 
treatment with 3-MA is strongly protective (60%) (Kaasik et al., 2005). This cell death is thus 
mainly due to the activation of autophagy, and partly independent of caspase-3, (the effect of 
inhibiting autophagy on caspase activation was not studied). Nerve growth factor deprivation 
induces the apoptosis of sympathic neurons in culture (caspase activation, cytochrome c 
release and DNA fragmentation), but also induces autophagy. 3-MA prevents the 
appearance of apoptotic features and protects against the neuronal death (Xue et al., 1999). 
However caspase inhibition (with boc-Asp-fmk) prevents neither the neuronal death nor the 
induction of autophagy. . 
In primary cortical neurons treated with the apoptotic stimulus staurosporine, 
enhanced autophagy contributes to caspase-dependent and independent apoptosis since 
autophagy inhibition (3-MA, Atg5 and Atg7 downregulation) is strongly neuroprotective and 
decreases both caspase-3 activation and AIF nuclear translocation (Grishchuk et al., 2011). 
Moreover, a combination of 3-MA and the pan-caspase inhibitor Q-VD-OPh is more 
protective than each inhibitor alone. Similar results are obtained with two other apoptotic 
stimuli, MK801 and etoposide. 
In excitotoxic conditions, dying neurons often present both autophagic and apoptotic 
features (Adhami et al., 2006; Ginet et al., 2009; Koike et al., 2008; Piras et al., 2011; Rami 
et al., 2008). The fact that inhibition of autophagy with 3-MA (Choi et al., 2012; Luo et al., 
2011; Piras et al., 2011; Puyal et al., 2009; Wang et al., 2008) or by knockout of atg7 (Koike 
et al., 2008) reduces apoptotic markers (caspase-3 and -9 activation or AIF translocation), 
but that caspase inhibition fails to affect autophagy (Puyal et al., 2009)(Puyal et al., 2009), 
suggests a role of autophagy in mediating apoptosis (Puyal and Clarke, 2009). In cerebral 
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ischemia, increased autophagy and apoptosis are detected in the same region (penumbra), 
suggesting that these two modes of neuronal death interact (Puyal et al., 2009; Rami et al., 
2008). In neonatal HI likewise, the induction of autophagy seems to be an important 
mechanism in neuronal death, but its role may depend on the brain region involved (Ginet et 
al., 2009). In the cortex, the classic morphologies of pure autophagic (type II) cell death or of 
pure apoptosis (type I) were never observed; the morphologies were always a mixture of the 
two suggesting that enhanced autophagy coexists with apoptosis and may trigger it. This is 
supported by results in neonatal focal cerebral ischemia where inhibition of autophagy with 3-
MA reduced apoptotic features (Puyal et al., 2009). But, in the hippocampus, cell death 
morphology tended to be purely apoptotic or purely autophagic (Ginet et al., 2009). In CA3 
the morphology of dying neurons was strongly autophagic and there was no activation of 
caspase 3 (Fig. 3C), whereas in CA1 cell death occurred more rapidly, had an apoptotic 
morphology, and was accompanied by caspase 3 activation.  
 Some studies have shown that lysosomal enzymes may be involved in excitotoxic 
neuronal death. Cathepsin B expression and activity increased following striatal injection of 
kainate (Wang et al., 2006), traumatic brain injury (Luo et al., 2010) or cerebral ischemia 
(Ginet et al., 2009; Nitatori et al., 1995; Puyal et al., 2009; Seyfried et al., 1997). Inhibition of 
this hydrolytic enzyme is neuroprotective and decreases apoptotic features (Luo et al., 2010; 
Seyfried et al., 1997; Wang et al., 2006; Wen et al., 2008). The death-mediating role of the 
cathepsin B activity is not understood, but one possibility is that it might be released from its 
normal lysosomal location into the cytosol, and kill by activating apoptosis through the 
cleavage of important protective proteins as Bid, Bcl-2, Bcl-xL or Mcl-1 (Repnik et al., 2012). 
This would imply a destabilization of lysosomal membranes, but whether this occurs in 
excitotoxicity is unclear. Some studies did indeed suggest a release of lysosomal enzymes 
during cerebral ischemia (Hill et al., 1997; Kilinc et al., 2010; Yamashima et al., 2003), but 
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others showed an increase in lysosomal activity (acid phosphatase, β-hexosaminidase) in 
apparently intact lysosomes or autolysosomes in hippocampal organotypic cultures exposed 
to NMDA (Borsello et al., 2003) and in models of cerebral ischemia (Puyal et al., 2009; Ginet 
et al., 2009).  
 
6.3. Interconnections between autophagy and necrosis  
Autophagy can also promote or inhibit necrosis, depending on the situation (Shen and 
Codogno, 2012). Autophagy promotes necrosis in MEF cells incapable of apoptosis (bax-/-
/bak-/- or overexpressing Bcl2) that are subjected to an ER stress for 2 or more days (Ullman 
et al., 2008). Autophagy likewise plays a pro-necrotic role in a model of neuronal death in the 
nematode C. elegans, where excessive autophagosome formation is induced early in the cell 
death process, and genetic or pharmacological inhibition of autophagy inhibits the 
development of necrosis (Samara et al., 2008). On the other hand, TNFα-induced autophagy 
in L929 cells appears to act as a negative feedback to necroptosis (Ye et al., 2011), and 
necrotic cell death during starvation-induced Dictyostelium discoideum development is 
enhanced when autophagy is inhibited by knockdown of atg1 (Luciani et al., 2009).  
The relationship between autophagy and necrosis in cerebral ischemia has scarcely 
been studied, but 3-MA treatment was shown to protect CA1 neurons against necrotic death 
in a severe model of adult global cerebral ischemia (Wang et al., 2011). 
 
7.  Development of neuroprotective strategies in the light of the multiple cell death 
mechanisms 
 
Despite the increasing knowledge on neuronal death and the important effort in 
research to identify neuroprotective agents, none have so far been translated to patients 
suffering from cerebral ischemia. The only pharmacological molecules approved in clinical 
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conditions are tissue-plasminogen activators (t-PA) to restore perfusion to adult ischemic 
brain. However t-PA has to be administrated within about 3h of stroke onset because of 
increased risk of intracranial hemorrhage and neurotoxic effects following delayed or 
prolonged use. For this reason very few patients (1-2%) can benefit from this treatment 
(Liberatore et al., 2003; Lopez-Atalaya et al., 2008; Stankowski and Gupta, 2011). For 
neonatal hypoxia-ischemia the only approved treatment is moderate hypothermia (Azzopardi 
et al., 2009; Gluckman et al., 2005; Shankaran et al., 2005; Shankaran, 2009). The 
development of a clinically safe and effective neuroprotectant is thus still an unmet goal for 
both adults and newborns. Among the difficulties in clinical trials, the heterogeneity of the 
ischemic insults is one of the most important. To maximize the chances of confirming a 
drug’s neuroprotective effect in humans, there is a need to design better-defined patient 
groups with more restricted conditions (Fisher, 2011; Gladstone et al., 2002; Tymianski, 
2010). 
Even if animal (mainly rodent) models of stroke and neonatal HI are imperfect 
imitations of human pathologies, experimental research on excitotoxic neuronal death has 
clearly demonstrated the complexity of the cell death pathways. The fact that multiple 
interacting cell death mechanisms are activated in neurons exposed to excitotoxic/ischemic 
stress has important implications for the design of neuroprotective therapy. Indeed, the failure 
of attempts so far to develop neuroprotective pharmacotherapy for ischemic stroke 
(Stankowski and Gupta, 2011; Yuan, 2009) and neonatal cerebral asphyxia (van Bel and 
Groenendaal, 2008) is probably due in part to the fact that inhibition of a particular death 
mechanism is ineffective when alternative ones can kill the cell. The optimal way to solve this 
problem is unknown, but the multiplicity of the pathways is illustrated in Fig. 7, which is highly 
simplified. An early approach was to inhibit the excitotoxic pathway at its origin, using NMDA 
receptor antagonists to block the massive calcium entry through these receptors. Intervening 
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at this early level has the advantage of inhibiting virtually all the death-mediating pathways, 
but unfortunately affects also those necessary for normal neuronal function and survival, 
generating many adverse side effects and necessitating the use of doses below the optimal 
ones for protection (Dingledine et al., 1999; Haberny et al., 2002; Hardingham and Bading, 
2003; Ikonomidou et al., 1999). Another problem is that the protective time window for NMDA 
receptor antagonists is only 1-2 h (Gladstone et al., 2002). Probably for these reasons, all 
clinical trials so far of NMDA receptor antagonists have failed (Ikonomidou and Turski, 2002). 
Alternative strategies have been developed to prevent complete inhibition of NMDA receptors 
and target downstream effectors. For example, promising results were obtained in preclinical 
studies with a peptide (NA-1 or Tat-NR2B9c) interrupting intracellular molecular pathway 
triggered by NMDA receptors activation in excitotoxic conditions by preventing interactions 
between postsynaptic density 95 (PSD95) and the NR2B subunits of the NMDA receptor 
(Aarts et al., 2002; Cook et al., 2012; Sun et al., 2008a; Tymianski, 2010).  
In the light of the multiple cell death mechanisms it may not be possible for a single 
neuroprotectant to have a long term protective effect. An alternative approach might be to 
intervene much further downstream, providing a cocktail of inhibitors against the separate 
death effector mechanisms (Culmsee et al., 2004; Fagan et al., 1999; Rogalewski et al., 
2006). The combination of two different agents might allow the doses of the individual drugs 
to be diminished, leading to reduced side effects (Park et al., 2007; Wang et al., 2012). 
Furthermore, there is evidence that early administration of one of the two drugs may delay 
deleterious events of the second one and extend the latter’s therapeutic time window (Kim et 
al., 2010; Ma et al., 2001) such as in thrombolytic strategies (Zhang et al., 2010; Zhang et al., 
2008). An application of such a window-extending strategy has been reported for inhibition of 
acid-sensing ion channel (ASIC) 1a, which contributes to neuronal calcium influx following 
cerebral ischemia and is involved in acidosis (Mari et al., 2010b). Acidosis occurs early in 
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cerebral ischemia and gates NMDA receptors. Psalmotoxin (PcTX), a specific ASIC1a 
inhibitor that is neuroprotective in murine models with a large time window, has been shown 
to extend the therapeutic time window of NMDA receptor inhibition with an additive effect 
(Pignataro et al., 2007; Xiong et al., 2004). Combination of pharmacological treatment with 
hypothermia, should also be considered (Cilio and Ferriero, 2010; Froehler and Ovbiagele, 
2010; Tang et al., 2009). Another therapeutic target that needs to be considered is the 
epigenetic modifications such as methylation of DNA or histones that occur following cerebral 
ischemia. Recent studies have shown that preventing these can be neuroprotective against 
stroke (Hwang et al., 2013; Noh et al., 2012). 
Such “polytherapy” could therefore allow, at least in theory, a longer therapeutic 
window. However intervening too late in the cell death cascades of events induced by a 
hypoxic/ischemic episode, at a downstream level where cellular damage has already begun, 
may be insufficient to prevent cell death. It may therefore be necessary to intervene at an 
intermediate level, downstream of calcium entry but upstream of particular death effector 
mechanisms. Before an optimal strategy can be devised, more research will be needed on 
the complex network of cascades linking excitotoxicity to apoptosis, autophagy and necrosis 
to identify the point of no return in the molecular cascades leading to neuronal death. 
However while anti-apoptotic agents such as caspase inhibitors are available for blocking 
most apoptosis, the specific blockade of autophagy requires RNA interference technology 
that would be difficult to use clinically; and, while necrosis can sometimes be prevented using 
calpain inhibition, this appears not to be a specific inhibitor of necrosis, but acts further 
upstream affecting various pathways. Recently it has been shown that the combination of 
necrostatin-1 (anti-necroptosis) (see above) with the peptide humanin (anti-apoptotic 
properties) (Hashimoto et al., 2001; Xu et al., 2006; Zapala et al., 2010) synergistically 
reduced lesion size and improved neurological outcomes in mice when administrated 4h after 
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MCAO (Xu et al., 2010). In general, preclinical studies of such combination treatments raise 
hope that clinically useful neuroprotection against ischemic brain damage may soon be 
achieved.  
 
8.  Conclusions 
There are at least three main types of cell death, all of which are triggered by active 
signaling and involve multiple signaling pathways. All the main types of cell death occur in 
neurons exposed to ischemia or to hypoxia-ischemia, and the multiple pathways interact. In 
particular situations a single pathway may predominate, in which case inhibition of a single 
group of enzymes, such as caspases, may give neuroprotection. But, in most situations, 
multiple pathways are involved and the development of clinical neuroprotection strategies will 
require an understanding of all the pathways and of their interactions. The discovery of a 
successful therapy, using a single agent or a cocktail to interfere with the diverse cell death 
pathways remains a challenge for researchers and clinicians.  
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Figure legends 
 
Fig. 1. Schematic description of the three main morphological types of cell death. (A) Healthy 
cell. (B) Type 1-Apoptosis. Nucleus: shrinkage, chromatin condensation, pyknosis, 
fragmentation. Plasma membrane: convolution, budding, formation of apoptotic bodies. 
Cytoplasm: shrinkage, organelles appear almost normal, but loss of ribosomes from the RER 
and polysomes. (C) Type 2-Autophagic cell death. Nucleus: sometimes shrinkage and 
moderate pyknosis. Plasma membrane: often intense endocytosis. Cytoplasm: numerous 
autophagosomes and autolysosomes, Golgi often enlarged. (D) Type 3– Necrosis. Nucleus: 
little change, but swelling. Plasma membrane: swelling and rounding up of cell, sometimes 
with rupture of plasma membrane. Cytoplasm: dilation of organelles, vacuolization. ER: 
endoplasmic reticulum. (Other type-3 subtypes exist). Inspired by Clarke (1990) and Clarke 
et al. (2008). 
 
Fig. 2. Simplified scheme of the intrinsic and extrinsic molecular pathways of apoptosis.  
The intrinsic (or mitochondrial) pathway is triggered by loss of integrity of the mitochondria 
and the release of proapoptotic molecules. The extrinsic pathway, also called the death-
receptor pathway, is activated by extracellular signals that involve the binding of extracellular 
proteins to “death receptors” on the cell membrane. Both pathways lead to caspase 
activation, but caspase-independent apoptosis can be triggered by the release of AIF and 
EndoG. AIF: apoptosis inducing factor; Apaf-1: adapter protein apoptotic protease-activating 
factor-1; Bax: Bcl-2–associated X protein; Bad: Bcl-2-associated death promoter; Bcl-2: B-
cell lymphoma 2; Bcl-xL: B-cell lymphoma-extra large; tBid: truncated BH3 interacting-domain 
death agonist; Bim: Bcl-2-interacting mediator of cell death; CAD: caspase-activated 
deoxyribonuclease; EndoG: endonuclease G; ER: endoplasmic reticulum; FADD: Fas-
associated death domain; FasL: Fas ligand; IAP: Inhibitor of Apoptosis Protein; IMM: inner 
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mitochondrial membrane; OMM: outer mitochondrial membrane; mPTP: mitochondrial 
permeability transition pore; Omi/HtrA2: High temperature requirement protein A2; PUMA: 
p53 upregulated modulator of apoptosis; Smac/Diablo: second mitochondria-derived activator 
of caspases/direct IAP binding protein with low pI; TNF: Tumor Necrosis Factor; TRAIL: TNF-
related apoptosis-inducing ligand. 
 
Fig. 3. Examples from our own research of the different morphological types of neuronal 
death after neonatal cerebral hypoxia-ischemia. (A) Healthy neuron in cortex of P12 rat. (B) 
Dying cortical neuron displaying apoptotic-like features after hypoxia-ischemia in P7 rat. 
Nuclear chromatin is clumped; cytoplasm is shrunken but mitochondria (m) appear almost 
normal. (C) Dying neuron with strong autophagic features after neonatal cerebral hypoxia-
ischemia at P7 (CA3 hippocampus). Nuclear surface is convoluted. Cytoplasm contains 
numerous autophagosomes and autolysosomes (see high magnification panel, top right) as 
well as empty vacuoles. (D) Dying neuron with necrotic features observed in the center of the 
cortical lesion after focal ischemia at P12. Contents of nucleus and cytoplasm are largely 
destroyed. Remaining organelles are dilated including mitochondria (m) and endoplasmic 
reticulum (ER). Plasma membrane appears ruptured (arrows). N: nucleus; Bars = 2µm.  
 
Fig. 4. Different forms of autophagy. Autophagy is an important physiological process 
involving intracellular degradation by lysosomes, acting in parallel with the proteasome 
system. The three different forms of autophagy differ in the mode of delivery of material to the 
lysosome. Microautophagy involves direct delivery. Chaperone-mediated autophagy is 
involved in the degradation of specific cytosolic proteins (with a KFERQ sequence) that are 
recognized by chaperone/co-chaperone complexes that then transport these proteins to the 
lysosome by interacting with LAMP2A. Macroautophagy consists in the sequestering of long-
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lived proteins and nonfunctional or damaged organelles to an intermediate compartment, the 
autophagosome, which will fuse with the lysosome to form an autolysosome in which the 
lysosomal hydrolases degrade the autophagosome content. LAMP: lysosomal associated 
membrane protein. 
 
Fig. 5. The molecular pathways of macroautophagy. Macroautophagy is a complex process 
driven by numerous protein-protein interactions between autophagy-related gene (Atg) 
proteins. Autophagosome biogenesis (green arrows) includes the nucleation of the pre-
autophagosome, its elongation, incurvation and closure. Source of membrane for 
autophagosome formation include a subdomain of ER called the omegasome, the Golgi 
apparatus, the outer membrane of mitochondria and the plasma membrane. Autophagosome 
maturation (blue arrows) involves fusion with a lysosome permitting the digestion of its 
content by lysosomal hydrolases at an acidic pH. The ULK1/2 complex acts in the initiation 
step. Beclin1 takes part in different complexes involved in autophagosome biogenesis: 
Beclin1/PI3K-III/Atg14L, Beclin1/PI3K-III/UVRAG. Bif-1 contributes to curvature of the 
membrane. LC3-II, the form of LC3 that is conjugated to a phosphatidylethanolamine (PE), 
plays an important role in autophagosome formation (elongation, curvature and end-to-end 
fusion). The Atg12-Atg5-Atg16L system and mAtg9 are essential for the elongation process. 
Atg7/Atg10 and Atg3/Atg4/Atg7 are enzymes implicated in conjugation of the Atg12-Atg5 and 
LC3 systems respectively. Proteins required for endocytosis such as Rab7 or ESCRT 
intervene also in the maturation of autophagosomes. Rubicon can bind to the Beclin1/PI3K-
III/UVRAG complex and inhibits the role of this complex in autophagosome maturation. Bif-1: 
Bax-interacting factor-1 or endophilin B1; ESCRT: endosomal sorting complex required for 
transport; LAMP: lysosomal associated membrane protein; LC3: microtubule-associated 
protein 1 light chain 3; Rubicon: RUN domain as Beclin 1-interacting and cysteine-rich 
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containing; ULK1/2: UNC-51-like kinase 1/2; UVRAG: UV irradiation resistance-associated 
gene. 
 
Fig. 6. The different involvements of autophagy in autophagy-associated cell death. Logically 
there are four possibilities. (A) Autophagic cell death can be defined as cell death mediated 
by autophagy without any sign of apoptosis or necrosis. Autophagy inhibition prevents or at 
least delays the cell death. (B) Autophagy-mediated cell death can be defined as apoptosis 
or necrosis mediated by autophagy. Cell death is prevented by inhibition of autophagy or of 
apoptosis/necrosis. (C) Autophagy may be epiphenomenal to the cell death, in which case 
inhibition of autophagy will not affect it. (D) Autophagy may play an anti-death role, in which 
case, inhibition of autophagy increases the cell death. 
 
Fig. 7. The main interconnections involved in the mediation of excitotoxicity-induced neuronal 
death, leading to the different cell death phenotypes. The arrows indicate pathways that may 
be direct or indirect. The short downward arrows under “ATP depletion” indicate that mild 
depletion promotes mitochondrial permeabilization whereas strong depletion promotes 
necrotic cell death. TRPC: transient receptor potential channel; PARP: Poly(ADP-Ribose) 
Polymerase; NMDAr: N-methyl-D-aspartate receptor; ASICs: acid-sensing ion channels.  
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